News

HCPs do not experience channels. They experience interactions. Life sciences brands create value when those interactions build confidence over time, and when strategy survives the journey into compliant, connected activation.

Omnichannel has the power to transform how life sciences brands connect with healthcare professionals (HCPs), patients and payors. But its value does not come from multiplying channels. It comes from orchestrating every interaction around how people actually seek information, weigh evidence and make decisions.

That distinction matters. An HCP may encounter a concise email, discuss a clinical question with a representative, hear peers debate new evidence at a congress and later return to a detailed digital resource. They are unlikely to regard these as separate channel experiences. They assemble confidence from fragments, across multiple touchpoints and over time.

The execution gap opens when the organization behind those interactions works differently. Insight, content, channels, field teams, medical, market access and local markets are often planned in silos. Each activity may be competent in isolation, yet the overall experience can still feel repetitive, disjointed or poorly timed. Strategic intent is weakened before it reaches the HCP.

Omnichannel excellence means closing that gap: turning a shared understanding of the audience into a connected sequence of relevant, compliant interactions, then learning from experience and improving upon it.

Start with how HCPs build confidence

A common misstep in pharma is shortcutting insight work because of time or budget pressure. This often results in content that misses the clinical question, patient-flow challenge or formulary hurdle shaping a decision. Creative and channel decisions then reflect internal preference rather than audience need.

Proprietary qualitative HCP research points to a useful three-stage filtering system. At the scan stage, an HCP asks, “Is this relevant to me?” and may decide within seconds. At triage, they ask, “Is this worth my time?” and may give the interaction one to three minutes. A deep dive happens when they decide, “I need to understand this,” creating the potential for 15 to 60 minutes of attention.

This is not a linear content journey. It is a practical reminder that every touchpoint has a different information task. A short asset should help an HCP recognize relevance or decide what deserves more attention. A deeper resource should provide the evidence, context or practical guidance needed to build confidence. Asking every asset to tell the whole story creates clutter, duplication and waste.

The strategic question is therefore not “Which channels should we use?” It is “What does this audience need from this interaction, in this context, to move towards a better-informed decision?” Channel choice follows that answer.

Build one journey across teams, not parallel plans

Successful orchestration begins with a structured, research-led foundation tailored to life sciences. HH Global uses focused strategic sessions, typically 90 minutes, to align teams, clarify roles, shape audience journeys and create launch-ready frameworks. The aim is not a static long-range roadmap. It is a shared operating foundation for continuous test-and-learn optimization.

That foundation brings four connected disciplines together:

1. Therapeutic and behavioral insight.The therapy landscape, unmet needs, competitive claims, access barriers and decision-critical evidence all shape the journey. HCPs may prioritize safety, efficacy, dosing and real-world evidence. Payors may focus on return on investment and economic impact. Carers and patient managers may need clear, accessible support pathways.




2. Audience mapping grounded in real input. Structured interviews, workshops and market research help turn broad audience labels into usable motivations, behaviors and information needs. The point is not to hard-code assumptions such as “General Practioners” prefer mobile or “specialists want detail.” It is to identify what matters to a defined audience in a defined situation.




3. Adoption-journey mapping The journey from awareness to assessment, trial and ongoing adoption should clarify the job of each interaction. A low-awareness HCP may need concise, data-led education. A competitor prescriber may need peer-to-peer discussion and real-world evidence. A trialist may need reassurance through key opinion leader content or platform discussion. A payor may need budget-impact and utilization insight.




4. Modular development, implementation and optimization. Insight must translate into content that is compliant, reusable and fitted to timing, channel and audience need. Clear approval pathways matter from the outset. HH Genius, HH Global’s AI-driven audience insights tool, can help identify content preferences, triggers and demographics so investment can be directed towards the productive areas.

Crucially, the journey must be shared by brand, medical, market access, sales and key account managers (KAMs), medical science liaisons (MSLs) and local market teams. Otherwise, the HCP experience the gaps: repeated messages, missing follow-up, conflicting priorities or content that arrives without the context needed to make it useful.

Match the channel to the information task

Context changes performance. Physical and digital formats each have roles to play, but neither is inherently superior. Print can still earn a glance and become more useful when an HCP can redistribute it to patients or colleagues. Email can provide a well-timed prompt but can disappear when HCPs feel bombarded. Short, bespoke video may answer a focused need more effectively than a long, generic webinar. Point-of-care digital tools may prove more useful than standalone apps or PDF downloads because they support a task at the moment it needs to be completed.

Podcasts offer a specific example of contextual fit. In a small proprietary qualitative sample, 13 of 19 HCPs mentioned podcasts. A 15 to 20-minute episode was described as a preferred “sweet spot,” while CME-linked episodes, expert discussants and clinically practical topics were seen as valuable. This does not make podcasts a universal answer. It shows how format, duration, authority and subject matter need to align with the listening context.

In-real-life engagement remains valuable for a different reason. Expert speakers, peer exchange, ring-fenced time away from clinical demands and serendipitous discovery can create conditions for deeper attention. In another small proprietary qualitative sample, 16 of 20 HCPs mentioned networking or peer exchange. Congresses, education events, KAM visits and representative detailing should therefore be treated as connected parts of the journey, not isolated offline tactics.

The same principle applies online across email, web, independent professional networks, webinars and mobile-first content. The purpose of orchestration is to let these interactions reinforce one another. A digital prompt before a field visit, for example, can establish relevance. The conversation can respond to the HCP’s questions. Follow-up content can then support deeper understanding without simply repeating the same message.

Design for attention, then validate what performs

Evidence from Healthcasts cited that more than 70% of HCPs use smartphones or tablets for clinical tools and research, around 88% prefer short video content, three to six-minute on-demand videos and 15 to 20-minute webinars perform best and infographics are the fastest-growing educational format.¹ These figures support the case for concise, self-directed and adaptable content across EMEA and North America.

Design content for reuse, learning and local activation

A connected experience depends on a connected content system. Modular content makes it easier to adapt approved evidence for different attention levels, channels, stakeholders and markets without rebuilding every asset from scratch. That can reduce wasted content, increase reuse and help local teams activate more effectively while maintaining the intended scientific and brand narrative.

It also creates a faster learning loop. Measurement should move beyond impressions and clicks to examine which messages and assets contribute to meaningful scientific engagement, field effectiveness, formulary-content usage, knowledge gain or behavioral change. Evidence of what performs can inform the next interaction, guide content investment and support faster optimization.

The commercial value should be framed carefully. Better orchestration does not guarantee a particular outcome. It can, however, create the conditions for higher-quality HCP engagement, more productive field conversations, less duplicated content, faster adaptation and a stronger return on the investment already being made across teams and channels.

Build compliance and regional relevance into the system

Life sciences activation must flex without fragmenting. The UK’s ABPI Code, Europe’s EFPIA Code and US FDA rules differ around claims, fair balance and patient-facing content. In EMEA, disease-education activity must avoid direct-to-patient promotion, while brands in the US can communicate directly with patients within the applicable regulatory framework. HCP needs also vary by role, therapy area, experience and market.

Launches, label extensions and market-access initiatives each require different sequences. Building claims, evidence, modularity, review requirements and local adaptation into the framework early allows markets to flex activation without losing strategic coherence or repeatedly starting again. This is where omnichannel becomes an operational capability rather than a campaign label.

Use technology to strengthen orchestration, not add complexity

AI is changing content creation, personalization and optimization. Large language model-indexed portals can help users surface credible scientific information, while predictive analytics can inform next-best actions for digital and field teams. Yet technology only closes the execution gap when it connects to governed content, defined roles, compliant workflows and useful measurement. Otherwise, it risks accelerating disconnected activity.

Closing the execution gap

HH Global’s perspective is straightforward: omnichannel excellence is not measured by the number of channels in a plan. It is measured by whether insight becomes a coherent, compliant and useful experience for the audience. That requires strategy to remain intact as content is developed, approved, adapted, activated by different teams and markets, measured and improved.

One of our patient-facing life sciences campaigns shows how connected activation can translate into measurable outcomes. A coordinated channel rollout, including display media, paid social and landing page performed different roles. StackAdapt delivered most awareness impressions, Meta generated the greatest click volume at the lowest CPC and Google accounted for the largest share of conversions. Overall, the campaign generated 5.48m impressions and 48,827 clicks. The landing page recorded 1,607 sample CTA clicks and 399 GA-tracked form fills, while video accounted for 86% of social clicks. Emerging performance data also informed the reallocation of spend towards the channels generating stronger engagement and conversion.

We close the execution gap between strategy and activation in life sciences by helping operationalize that strategy across content, channels, teams, markets and measurement. The role is to connect the moving parts, create an executable framework and help every interaction contribute to the same audience journey.

See how we can help you close the execution gap and turn disconnected touchpoints into an HCP experience that builds confidence, supports better decisions and delivers more value from every interaction.

Reference:

1. https://healthcasts.com/life-sciences-blog/understanding-hcp-content-preferences-in-2025